DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $355,227,702 | -48.1% | 1,646,860 | -43.0% | 0.60% | -42.5% |
Q2 2023 | $684,257,285 | +1.3% | 2,889,478 | +7.8% | 1.04% | -0.6% |
Q1 2023 | $675,564,235 | -4.8% | 2,680,385 | +0.3% | 1.04% | -11.9% |
Q4 2022 | $709,324,865 | +4.9% | 2,672,462 | +2.1% | 1.18% | +1.9% |
Q3 2022 | $675,930,000 | -1.4% | 2,616,942 | -3.2% | 1.16% | +5.9% |
Q2 2022 | $685,430,000 | -15.1% | 2,703,651 | -1.8% | 1.10% | +1.5% |
Q1 2022 | $807,290,000 | +3.2% | 2,752,156 | +15.8% | 1.08% | +2.7% |
Q4 2021 | $782,011,000 | +17.6% | 2,376,860 | +8.8% | 1.05% | +11.8% |
Q3 2021 | $664,781,000 | +1.7% | 2,183,618 | -10.3% | 0.94% | +3.7% |
Q2 2021 | $653,550,000 | +31.4% | 2,435,347 | +10.2% | 0.91% | +19.9% |
Q1 2021 | $497,352,000 | +6.2% | 2,209,667 | +4.8% | 0.76% | -25.0% |
Q4 2020 | $468,385,000 | +0.0% | 2,108,511 | -3.0% | 1.01% | -13.1% |
Q3 2020 | $468,168,000 | +22.4% | 2,174,187 | +0.5% | 1.16% | +13.7% |
Q2 2020 | $382,386,000 | +17.7% | 2,162,448 | -7.9% | 1.02% | -2.0% |
Q1 2020 | $324,917,000 | -11.7% | 2,347,500 | -2.1% | 1.04% | +15.6% |
Q4 2019 | $368,012,000 | -6.2% | 2,397,787 | -11.8% | 0.90% | -12.4% |
Q3 2019 | $392,422,000 | -9.5% | 2,717,042 | -10.4% | 1.03% | -7.9% |
Q2 2019 | $433,612,000 | -0.8% | 3,033,946 | -8.3% | 1.12% | +6.2% |
Q1 2019 | $436,974,000 | +113.0% | 3,309,911 | +66.4% | 1.05% | +95.5% |
Q4 2018 | $205,152,000 | +7.1% | 1,989,448 | +12.9% | 0.54% | +15.7% |
Q3 2018 | $191,537,000 | +19.0% | 1,762,719 | +8.1% | 0.47% | +13.4% |
Q2 2018 | $160,979,000 | -6.0% | 1,631,321 | -6.7% | 0.41% | -5.7% |
Q1 2018 | $171,172,000 | +6.6% | 1,748,260 | +1.0% | 0.44% | +12.4% |
Q4 2017 | $160,627,000 | +0.6% | 1,730,523 | -7.0% | 0.39% | -54.9% |
Q3 2017 | $159,699,000 | +8.1% | 1,861,730 | +6.4% | 0.86% | +4.7% |
Q2 2017 | $147,717,000 | -3.6% | 1,750,404 | -2.3% | 0.82% | -8.4% |
Q1 2017 | $153,304,000 | -16.7% | 1,792,398 | -24.2% | 0.90% | -18.6% |
Q4 2016 | $183,968,000 | -1.5% | 2,363,415 | -0.8% | 1.10% | -5.5% |
Q3 2016 | $186,680,000 | +1.9% | 2,381,421 | -0.5% | 1.17% | +12.7% |
Q2 2016 | $183,210,000 | -12.5% | 2,393,356 | +8.4% | 1.04% | -45.5% |
Q1 2016 | $209,450,000 | +0.0% | 2,207,993 | -2.1% | 1.90% | +46.2% |
Q4 2015 | $209,402,000 | +3.7% | 2,254,541 | -4.9% | 1.30% | +6.0% |
Q3 2015 | $201,995,000 | +1.0% | 2,370,560 | +1.4% | 1.23% | +13.0% |
Q2 2015 | $200,043,000 | +2.2% | 2,337,227 | +1.3% | 1.08% | +5.1% |
Q1 2015 | $195,808,000 | +1.7% | 2,306,335 | +2.7% | 1.03% | +5.1% |
Q4 2014 | $192,543,000 | +10.8% | 2,246,453 | -1.8% | 0.98% | +12.7% |
Q3 2014 | $173,803,000 | -2.2% | 2,287,485 | +1.3% | 0.87% | +5.3% |
Q2 2014 | $177,778,000 | +19.4% | 2,258,075 | +13.7% | 0.83% | +13.3% |
Q1 2014 | $148,955,000 | -0.5% | 1,986,068 | +2.5% | 0.73% | -3.4% |
Q4 2013 | $149,634,000 | -0.4% | 1,938,268 | -10.5% | 0.76% | -0.5% |
Q3 2013 | $150,163,000 | +11.7% | 2,166,236 | +2.0% | 0.76% | +18.6% |
Q2 2013 | $134,384,000 | – | 2,122,967 | – | 0.64% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |